A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs INCB 47986 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
Most Recent Events
- 22 Feb 2015 Status changed from recruiting to suspended according to ClinicalTrials.gov record.
- 28 Mar 2014 New trial record